At a June 21 joint meeting, the NCI Board of Scientific Advisors and the National Cancer Advisory Board approved three concepts and deferred one:
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
